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ABSTRACT
Background: Despite evidence that opioids might relieve chronic breathlessness, physicians may still be
reluctant to prescribe them due to safety concerns. By contrast, benzodiazepine (BDZ) prescribing often
seeks to reduce chronic breathlessness despite no evidence of net benefit. Prescribing patterns and
indications for these medications in severe interstitial lung disease (ILD) are unknown. Here, our objective
was to evaluate the indications, medications and temporal patterns of BDZ and opioid prescriptions in
people with oxygen-dependent ILD.
Methods: This was an observational, population-based, longitudinal study of adults starting long-term
oxygen therapy (LTOT) for ILD between 2005 and 2014 in the Swedish National Registry for Respiratory
Failure (Swedevox). People dispensed BDZs (n=2000) and opioids (n=2000) from 6 months before start of
LTOT throughout follow-up (first of death or study end) were analysed.
Results: Of 1635 included patients, 651 (39.8%) received BDZs and 710 (43.4%) received opioids during the
study period; 373 (22.8%) patients received both. The most frequently prescribed BDZs and opioids were
oxazepam (85.6%) and oxycodone (28.7%), respectively. Indications for breathlessness were uncommon for
BDZs (1.4%) and opioids (6.4%). During the last year of life, opioid indications for breathlessness increased
from 2.5% (12–10 months before death) to 10.2% in the last 3 months of life (p=0.048).
Conclusions: In oxygen-dependent ILD, opioids are rarely prescribed for breathlessness even in the last
months of life, when chronic breathlessness often increases in prevalence and intensity.
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INTERSTITIAL LUNG DISEASE
Introduction
Interstitial lung disease (ILD) is a growing group of disorders that cause fibrosis of the alveoli, distal airways and
septal interstitium of the lungs [1]. ILD is associated with poor survival and had ∼50% increase in mortality
globally between 2007 and 2017 [2]. The clinical features include worsening symptoms, declining activity and
fitness, and, in advanced disease, respiratory distress at rest [3, 4]. Breathlessness is the predominant symptom
in severe ILD, and is associated with deteriorating health-related quality of life and increased risk of hospital
admission and premature death [5–9]. As the disease progresses, disabling breathlessness becomes persistent
despite optimal treatment of the underlying disease(s), i.e. chronic breathlessness [10].
Evidence supports the use of systemic (non-nebulised) morphine for the symptomatic relief of chronic
breathlessness in patients with a variety of diseases [11]. Significant reductions of breathlessness intensity
have been shown for low-dose, systemic morphine [12–14]. The risk of respiratory depression is low when
treated with regular, low-dose morphine, and no association between opioids used for breathlessness and
increased hospital admissions has been reported [14, 15]. Neither low-dose nor high-dose opioids have
shown association with increased mortality in ILD [14].
Benzodiazepines (BDZs) are used to treat anxiety and are sometimes prescribed for the relief of
breathlessness, but the evidence on effectiveness is insufficient [16].
Physicians may be reluctant to prescribe regular, low-dose morphine due to fear of adverse effects,
insufficient knowledge of initiation and titration, and a lack of current treatment guidelines [17–19]. No
study has evaluated the indications for prescribed opioids and BDZs for patients with ILD. A comparison
of prescribing practice in BDZs (lack of evidence for effectiveness in breathlessness) and opioids (evidence
for effectiveness in breathlessness) is of interest.
The aim of this study was to evaluate the indications, medications used and temporal patterns of opioid
and BDZ prescriptions in people with oxygen-dependent ILD.
Material and methods
Design and population
This was an observational, population-based, longitudinal cohort study of prescriptions for BDZs and
opioids received by patients aged ⩾18 years, starting long-term oxygen therapy (LTOT) for
physician-diagnosed ILD between October 1, 2005 and December 31, 2014, in the Swedish National
Registry for Respiratory Failure (Swedevox) [20]. If a patient started LTOT more than once during the
study period, only the most recent LTOT episode was included. The design is similar to a previous study
using the Swedevox registry database to investigate indications for opioids in patients with
oxygen-dependent chronic obstructive pulmonary disease (COPD) [21].
Assessments
The following patient-level data were collected from Swedevox at the start of LTOT (baseline) [20]: age,
sex, forced expiratory volume in 1 s (FEV1) % predicted, vital capacity (VC) % predicted, FEV1/VC, and
arterial oxygen tension (PaO2) and arterial carbon dioxide tension (PaCO2) while breathing air and oxygen.
The data in Swedevox, including the ILD diagnosis, spirometry and blood gases, were recently validated
with high concordance with medical records [22].
Data on dispensed drug prescriptions were obtained from the Swedish Prescribed Drug Register, which
includes all dispensed prescriptions during outpatient care nationwide. A random sample of the cohort’s
dispensed BDZ (random sample of n=2000) and opioid (n=2000) prescriptions was taken from the time
period between 6 months prior to starting LTOT and end of follow-up (the earliest of either date of death
or study end). Prescriptions from 6 months before the patients started LTOT were included to capture
drugs that may have been prescribed earlier but used during the study period. Data on type of BDZ or
opioid medication, defined daily doses, dosing type (as-needed or regular dosing) and the free-text
indication(s) were obtained from the registry. Indications were not mutually exclusive and were categorised
as breathlessness, pain, anxiety, other or missing.
Ethical considerations
The study was approved by the Lund University (Lund, Sweden) Research Ethics Committee (2016/846)
and the Swedish National Board of Health and Welfare. Individual patient consent was not required as the
study used de-identified data aggregated nationally.
Statistical analyses
Baseline patient characteristics were summarised for all ILD patients receiving BDZ or opioid prescriptions
during the study period, and for patients with prescriptions in the random sample, separately for those
with known and unknown indications.
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To understand differences in recording practices, the proportion of known and unknown indications
was described by the year the prescription was filled and how the product was prescribed: 1) “dose”
prescriptions, for patients who typically receive drugs organised into daily doses to assist them in
taking the correct amounts or patients receiving one-off prescriptions, and 2) all other “regular”
prescriptions.
Prescriptions were evaluated in two steps: 1) all dispensed prescriptions in the random sample during the
study period were analysed to describe the type of prescribed medication, defined daily doses and dosing
schedule (regular, as-needed or both), and 2) indications (breathlessness, pain, anxiety, other or missing)
were described for all dispensed prescriptions in the random sample, excluding “dose” prescriptions before
2012, as this type of prescription did not include indication text in the Prescribed Drug Register before
that date. Indications were described for BDZ and opioid prescriptions overall, and separately for two time
periods: 6 months before LTOT start and the last 6 months of LTOT. Variations in indications over the
last 12 months of life were described for prescriptions filled by patients who died while receiving LTOT.
Prescriptions could contain more than one indication and could be for regular dosing and “as-needed”
dosing simultaneously.
We used mean and standard deviation to describe normally distributed variables, median and interquartile
range (IQR) for variables with skewed distributions, and frequency and percentage for categorical data.
The Chi-squared test was used to test for differences between groups; statistical significance was set at
p<0.05. Analyses were performed using Stata version 14.2 (StataCorp, College Station, TX, USA).
Results
A total of 1635 patients with fibrotic ILD started LTOT between October 1, 2005 and December 31, 2014.
Opioids were received by 710 (43.4%) and BDZs by 651 (39.8%) patients during the study period, and 373
(22.8%) patients received both opioids and BDZs.
Patients who used BDZs were aged 76.2±8.8 years and 41.9% were female; patients who used opioids were
aged 75.7±9.5 years and 44.1% were female (table 1).
The random samples of 2000 opioid and 2000 BDZ prescriptions were filled by a total of 744 patients, of
whom 470 patients filled opioid prescriptions, 486 filled BDZ prescriptions, and 212 patients in the
random sample filled both BDZ and opioid prescriptions.
Indications were known in 52.1% of BDZ prescriptions and 54.4% of opioid prescriptions included in the
random sample. Missing indications were largely due to the fact that indications were not registered for
“dose” prescriptions before 2012; 72.3% of “dose” prescriptions had unknown indications compared with
27.4% of “regular” prescriptions (p<0.001). Characteristics were similar between patients with unknown
and known indications (supplemental table S2).
TABLE 1 Characteristics of oxygen-dependent interstitial lung disease patients
All patients Patients prescribed benzodiazepines Patients prescribed opioids
Patients 1635 651 710
Age years 76.3±9.0 76.2±8.8 75.7±9.5
Female 606 (37.1) 273 (41.9) 313 (44.1)
FEV1 % pred 68.4±24.4 67.1±21.8 66.5±23.3
Missing 689 (42.1) 269 (41.3) 308 (43.4)
VC % pred 57.7±23.0 56.1±19.8 57.1±21.2
Missing 694 (42.4) 269 (41.3) 309 (43.5)
FEV1/VC 0.8±0.4 0.9±0.6 0.8±0.1
Missing 648 (39.6) 256 (39.3) 291 (41.0)
PaO2 air kPa 6.6±1.0 6.7±1.0 6.6±1.0
Missing 367 (22.4) 150 (23.0) 162 (22.8)
PaCO2 air kPa 5.1±1.0 5.1±0.9 5.2±0.9
Missing 375 (22.9) 152 (23.4) 164 (23.1)
Follow-up days 228 (82–512) 280 (111–570) 304.5 (118–646)
Data are presented as n, mean±SD, n (%) or median (interquartile range). FEV1: forced expiratory volume in
1 s; VC: vital capacity; PaO2: arterial oxygen tension (breathing air); PaCO2: arterial carbon dioxide tension
(breathing air).
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Types of BDZs and opioids
The most frequently dispensed BDZ was oxazepam (85.6%) and BDZ prescriptions were most commonly
prescribed as “as-needed” doses (44.4%), as shown in table 2. For opioids, the most common medication
was oxycodone (28.7%) and opioids were most frequently prescribed for regular dosing (39.9%).
Indications and temporal patterns
The predominant indication for BDZs was anxiety (96.9%) and for opioids was pain (94.8%) over the
study period. Indications by drug type are shown in table 3. The main opioid prescribed for breathlessness
was morphine.
Indications for breathlessness remained low for BDZs throughout follow-up, increasing from 0.5% in the
6 months before starting LTOT to 2.2% in the last 6 months of LTOT (p=0.13). For opioids, indications
for breathlessness were low, but there was a small but significant increase from 1.4% in the 6 months
before starting LTOT to 9.6% in the last 6 months of LTOT (p<0.001) (table 4).
Figure 1 shows the trend for indications in the last 12 months of life for patients who died while receiving
LTOT (see supplementary table S2 for the data). The stated indications for BDZ prescriptions remained
stable over the last 12 months of life, with indications for anxiety most common (96.5%). For opioid
prescriptions, indications for pain were most common (94.2%), but there was a small but statistically
significant increase in indications for breathlessness, increasing from 2.5% (12–10 months before death) to
10.2% in the last 3 months of life (p=0.048).
Over time, the proportion of patients who were dispensed the medications declined slightly. Between
2007–2009 and 2012–2014, the proportion of patients using BDZs decreased from 42.2% to 37.2%
(p=0.096) and for opioids from 46.6% to 38.4% (p=0.006). However, there were no time trends for
treatment during the last 6 months of LTOT, neither for BDZs (38.2% versus 35.4%; p=0.35) nor for
opioids (34.0% versus 32.8%; p=0.68).
Discussion
In patients with severe oxygen-dependent ILD, breathlessness as an indication for prescription was rare
overall at 1.4% for BDZ prescriptions and 6.4% for opioid prescriptions. Indications for breathlessness
were low but increased slightly over the LTOT treatment period for opioids, and remained low and stable
throughout the treatment period for BDZs. These findings suggest that patients with severe
oxygen-dependent ILD, many of whom are likely to suffer chronic respiratory symptoms [5], are rarely
treated with these medications even at the end of life.
Chronic breathlessness is very common in severe ILD, including at the end of life [7, 9, 14]. Palliative and
end-of-life care is of crucial importance for these severely ill patients with a high symptom burden.
TABLE 2 Benzodiazepine (BDZ) and opioid prescriptions for patients with oxygen-dependent
interstitial lung disease
BDZs Opioids
Prescriptions (random sample) 2000 2000
DDDs per prescriptions 33.0±37.4 19.7±28.2
Missing 0 (0.0) 18 (0.9)
BDZ
Oxazepam 1712 (85.6)
Diazepam 139 (7.0)
Alprazolam 123 (6.2)
Other 26 (1.3)
Opioid
Codeine 269 (13.5)
Dextropropoxyphene 97 (4.9)
Fentanyl 132 (6.6)
Morphine 440 (22.0)
Oxycodone 573 (28.7)
Tramadol 384 (19.2)
Other 105 (5.3)
Data presented as n, mean±SD or n (%); percentages do not sum to 100 due to rounding. DDDs: defined
daily doses.
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A previous study found lower use of structured symptom assessments for end-of-life patients with ILD
compared with people diagnosed with lung cancer [9], which may lead to poorer recognition and fewer
attempts to control symptoms. In line with the present findings, opioids are also rarely prescribed for
breathlessness in COPD in Sweden, where the incidence of opioids was only 4% in the last 6 months of
life [21]. Similar findings were seen in COPD patients at a hospital in France, where, despite having
chronic breathlessness, none of the included patients received opioids [23].
Our finding that indications for breathlessness are more common for opioid than BDZ prescriptions
potentially reflects, at least partly, the availability of evidence supporting the use of opioids in the
treatment of breathlessness (mainly extrapolated from patients with COPD and other severe illness) and
the corresponding lack of evidence supporting the use of BDZs for breathlessness [12, 13, 16, 24]. The
TABLE 3 Opioid and benzodiazepine (BDZ) indications by drug type
Pain Breathlessness Anxiety Other
Opioid
Codeine 149 (98.7) 0 (0.0) 0 (0.0) 7 (4.6)
Morphine 225 (83.6) 52 (19.3) 16 (5.9) 19 (7.1)
Dextropropoxyphene 35 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Fentanyl 72 (97.3) 3 (4.1) 0 (0.0) 0 (0.0)
Oxycodone 288 (97.3) 12 (4.1) 1 (0.3) 2 (0.7)
Tramadol 196 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Other 65 (98.5) 3 (4.5) 0 (0.0) 0 (0.0)
Total 1030 70 17 28
p-value <0.001 <0.001 <0.001 <0.001
BDZ
Alprazolam 0 (0.0) 0 (0.0) 76 (100.0) 2 (2.6)
Diazepam 1 (1.2) 0 (0.0) 68 (84.0) 16 (19.8)
Oxazepam 1 (0.1) 15 (1.7) 862 (97.8) 34 (3.9)
Other 0 (0.0) 0 (0.0) 3 (100.0) 1 (33.3)
Total 2 15 1009 53
p-value 0.17 0.43 <0.001 <0.001
Data are presented as n (%) or n, unless otherwise stated; percentages do not sum to 100 as multiple
indications could be stated.
TABLE 4 Indications for random samples of benzodiazepine (BDZ) and opioid prescriptions in
oxygen-dependent interstitial lung disease
Overall 6 months before starting LTOT Last 6 months of LTOT p-value
Prescriptions 3039 489 860
BDZs
Known indication
Pain 2 (0.2) 1 (0.5) 0 (0.0) 0.127
Breathlessness 15 (1.4) 1 (0.5) 10 (2.2) 0.127
Anxiety 1009 (96.9) 193 (96.5) 454 (97.4) 0.511
Other 53 (5.1) 12 (6.0) 29 (6.2) 0.913
Unknown indication 387 (27.1) 76 (27.5) 167 (26.4) 0.718
Opioids
Known indication
Pain 1030 (94.8) 284 (98.3) 364 (92.4) 0.001*
Breathlessness 70 (6.4) 4 (1.4) 38 (9.6) <0.001*
Anxiety 17 (1.6) 0 (0.0) 12 (3.1) 0.003*
Other 28 (2.6) 5 (1.7) 12 (3.1) 0.276
Unknown indication 524 (32.5) 102 (26.1) 211 (34.9) 0.004*
Data are presented as n or n (%), unless otherwise stated. LTOT: long-term oxygen therapy. Data for
“dose” prescriptions before 2012 were excluded as they lacked data on indications in the Prescribed Drug
Register. *: p<0.05 (Chi-squared test).
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number of opioid indications for breathlessness remained low, suggesting that uncertainty around safety
and effectiveness could be a barrier to greater use of opioids. Lack of indications for breathlessness in
opioid prescriptions could also be due to breathlessness being overlooked as a therapeutic target. In our
sample, BDZs were prescribed for breathlessness in a small number of cases, despite the lack of evidence
for effectiveness. Possible explanations for this include prescribing BDZs for breathlessness as a second
choice following unsuccessful use of opioids or prescribing for anxiety in the presence of breathlessness as
these symptoms commonly occur together [25–27].
BDZs were mostly prescribed “as-needed”, reflecting their main indication for anxiety. Opioids were
mostly prescribed for regular dosing, reflecting their main indication for (chronic) pain.
A strength of this study is the use of national registry (Swedevox) data with nationwide coverage yielding
high external validity to patients in Sweden and similar high-income settings [20]. A further strength is
that the study evaluated a large random sample of dispensed prescriptions longitudinally that is likely to
be representative of all dispensed prescriptions for the cohort. A limitation was missing data on some of
the clinical characteristics, which reflects the nature of the clinical register data used for this study. Data
from the patients’ medical records were not available and therefore could not be used to cross-validate the
free-text indications. It is possible that the indications for breathlessness were underestimated as the
medications may have been prescribed for breathlessness in conjunction with another symptom (with only
the latter stated as an indication), e.g. in BDZs prescribed for anxiety related to breathlessness, and in
patients with concurrent pain and breathlessness.
The findings in this study form the baseline for future research to evaluate temporal trends in prescribing
both opioids and BDZs to patients with ILD. The results indicate that chronic respiratory symptoms may
be undertreated in patients with oxygen-dependent ILD, which warrants further evaluation. The results
may also contribute to identify possible improvements for clinicians regarding treatment in severe ILD to
improve the overall wellbeing of patients.
The present findings have several important implications. It would be desirable that the high prevalence of
prescribed tramadol be reduced for this seriously ill and elderly population as it is not recommended due to
side-effects (especially from drug–drug interactions) that may pose a danger. However, tramadol prescription
may have declined since the end of the study period in 2014. Trends in prescription for breathlessness over
the years could not be evaluated due to the low number of prescriptions for breathlessness overall. The
finding that many prescriptions lacked an indication indicates the need for clinicians to improve the stated
indications. In order to introduce evidence-based opioid therapy for breathlessness in severe ILD, more
research (including randomised controlled trials of symptomatic treatment) is needed to inform opioid
treatment efficacy and safety.
In conclusion, in oxygen-dependent ILD, BDZs and opioids are rarely prescribed for breathlessness even
in the last months of life in a population with a high prevalence of chronic breathlessness that often
worsens as death approaches.
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FIGURE 1 Trends for indications in random samples of a) 552 opioid and b) 594 benzodiazepine prescriptions
for deceased patients with oxygen-dependent interstitial lung disease (known indications in the last
12 months of life).
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